Update: Tuberkulose bei Erwachsenen in Deutschland

Zusammenfassung

In Deutschland ist die Tuberkulose mit einer Inzidenz von 5,6 / 100000 weiterhin selten. Allerdings nehmen seit 2013 die Fallzahlen erstmals seit mehr als 60 Jahren wieder zu. V. a. in der Betreuung von Migranten sind daher Kenntnissebezüglich der klinischen Präsentation, Diagnostik und Therapie der Tuberkulose wichtig. Der breite Einsatz molekularer Analyseverfahren wird in naher Zukunft die Therapieplanung deutlich erleichter. Neu entwickelte Medikamente ermöglichen es inzwischen, auch die immer häufigeren Fälle mit Medikamentenresistenz erfolgreich zu therapieren.

Abstract

With an incidence of 5.6/100000 tuberculosis remains rare in Germany. However, for the first time since over 60 years, case numbers have started to increase since 2013. Therefore, knowledge of the clinical presentation as well as diagnostic and therapeutic approaches is important, specifically when caring for migrant patients. The broad use of molecular analyses will soon facilitate the choice of therapeutic regimens, novel drugs already enable us to successfully treat also the increasing numbers of drug-resistant tuberculosis cases.

Schlüsselwörter

Tuberkulose - LTBI - Interferon-γ-Release Assay (IGRA) - Isoniazid - Rifampicin

Keywords

tuberculosis - LTBI - interferon-γ-release assay (IGRA) - isoniazid - rifampincine

• Literatur

• 1 World Health Organization. Global tuberculosis report 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf letzter Zugriff am 23.2.2016
• 2 The United Nations Development Group. Millenium project: goals, targets and indicators. http://www.unmillenniumproject.org/goals/gti.htm#goal6 letzter Zugriff am 23.2.2016
• 3 The United Nations Development Programme. Goal 3: Ensure healthy lives and promote well-being for all at all ages. http://www.un.org/sustainabledevelopment/health/ letzter Zugriff am 23.2.2016
• 4 European Centre for Disease Prevention and Control / WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. http://ecdc.europa.eu/en/publications/Publications/tuberculosis-surveillance-monitoring-Europe-2015.pdf letzter Zugriff am 23.2.2016
• 5 Robert Koch Institut. Tuberkulose in Deutschland. Ende des rückläufigen Trends? Epid Bull 2015; 43: 461-463
• 6 Robert Koch Institut. Bericht zur Epidemiologie der Tuberkulose in Deutschland für 2014. http://www.rki.de/DE/Content/InfAZ/T/Tuberkulose/Download/TB2014.pdf letzter Zugriff am 23.2.2016
• 7 Michels H, Bartz C. Tuberkulose-Screening im Rahmen der infektionshygienischen Untersuchung Asylbegehrender in Rheinland-Pfalz, Trier. Epid Bull 2015; 11 (12) 88-89
• 8 Chen WJ, Chen CH, Shih CH. Surgical treatment of tuberculous spondylitis. 50 patients followed for 2-8 years. Acta orthopaedica Scandinavica 1995; 66: 137-142
• 9 Kulchavenya E, Kholtobin D. Diseases masking and delaying the diagnosis of urogenital tuberculosis. Therap adv urol 2015; 7: 331-338
• 10 Robert Koch Institut. HIV-Testung bei Tuberkulose-Diagnose: eine Selbstverständlichkeit?. Epid Bull 2014; 48: 463-471
• 11 Wergeland I, Pullar N, Assmus J et al. IP-10 differentiates between active and latent tuberculosis irrespective of HIV status and declines during therapy. J infect 2015; 70: 381-391
• 12 Collins LF, Geadas C, Ellner JJ. Diagnosis of latent tuberculosis infection: too soon to pull the plug on the tuberculin skin test. Ann intern med 2016; 164: 122-124
• 13 Lange C, van Leth F, Sester M. Viral load and risk of tuberculosis in HIV-infection. J Acquir Immune Defic Syndr 2016; 71: e51-53
• 14 Leonard MK, Osterholt D, Kourbatova EV et al. How many sputum specimens are necessary to diagnose pulmonary tuberculosis?. Am J Infect Contr 2005; 33: 58-61
• 15 Ziegler R, Just HM, Castell S et al. Infektionsprävention bei Tuberkulose – Empfehlungen des DZK. Pneumologie 2012; 66: 269-282
• 16 Cepheid Xpert MTB/RIF Package Insert. http://www.cepheid.com/us/mtbrif-pi letzter Zugriff am 23.2.2016
• 17 U.S. Food and Drug Administration. News release: New data shows test can help physicians remove patients with suspected TB from isolation earlier. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm letzter Zugriff am 28.12.2015
• 18 Bryant JM, Lipman M, Breuer J. Personalizing therapy for multidrug resistant TB: the potential of Rapid Whole Genome Sequencing. Expert Rev Anti Infect Ther 2016; 14: 1-3
• 19 Van’t Hoog AH, Bergval I, Tukvadze N et al. The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study. BMC infect dis 2015; 15: 473
• 20 World Health Organization. Treatment of Tuberculosis Guidelines, Fourth Edition. http://www.who.int/entity/tb/publications/tb_treatmentguidelines/en/index.html letzter Zugriff am 23.2.2016
• 21 Schaberg T, Bauer T, Castell S et al. Empfehlungen zur Therapie, Chemoprävention und Chemoprophylaxe der Tuberkulose im Erwachsenen- und Kindesalter. Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose (DZK), Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin (DGP). Pneumologie 2012; 66: 133-171
• 22 Horsburgh Jr CR, Barry 3rd CE, Lange C. Treatment of Tuberculosis. N Engl J Med 2015; 373: 2149-2160
• 23 Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and management of peripheral tuberculous lymphadenitis. Clin Infect Dis 2011; 53: 555-562
• 24 Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-629
• 25 World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf letzter Zugriff am 23.2.2016
• 26 World Health Organization. The use of delamanid in the treatment of multidrug-resistant tuberculosis. Interim policy guidance. http://www.ncbi.nlm.nih.gov/books/n/whodela/pdf/ letzter Zugriff am 23.2.2016
• 27 Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151-2160
• 28 Olaru ID, von Groote-Bidlingmaier F, Heyckendorf J et al. Novel drugs against tuberculosis: a clinician‘s perspective. Europ Resp J 2015; 45: 1119-1131
• 29 Rangaka MX, Cavalcante SC, Marais BJ et al. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection. Lancet 2015; 386: 2344-2353
• 30 Dheda K, Barry 3rd CE, Maartens G. Tuberculosis. Lancet 2015; DOI: 10.1016/S0140-6736(15)00151-8.
• 31 Getahun H, Matteelli A, Abubakar I et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Europ Resp J 2015; 46: 1563-1576
• 32 Diel R, Goletti D, Ferrara G et al. Interferon-gamma release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Europ Resp J 2011; 37: 88-99
• 33 Elzi L, Schlegel M, Weber R et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44: 94-102
• 34 Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morbidity and mortality weekly report 2011; 60: 1650-1653